Hypoxia, angiogenesis and cancer therapy: To breathe or not to breathe?

Cell Cycle

Volumn 8, Issue 20, 2009, Pages 3291-3296

  Michieli, Paolo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Angiogenesis; Hepatocyte growth factor; Hypoxia; Invasive growth; Metastasis; Myoglobin; Target therapy

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOGENESIS INHIBITOR; CYTOCHROME C OXIDASE; DH 101; ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MYOGLOBIN; NITRIC OXIDE; OXYGEN; REACTIVE OXYGEN METABOLITE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SU 10944; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CANCER CELL; CANCER INVASION; CANCER THERAPY; CARCINOGENESIS; CELL ACTIVITY; CELL DIVISION; CELL FUNCTION; CELL HYPOXIA; CELL VIABILITY; DRUG MECHANISM; GLYCOLYSIS; HYPERBARIC OXYGEN; MALIGNANT TRANSFORMATION; NONHUMAN; OXYGEN DIFFUSION; OXYGEN TRANSPORT; OXYGENATION; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH;

EID: 70350244837     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.20.9741     Document Type: Review

References (55)

1. Brahimi-Horn MC, Chiche J, Pouysségur J. Hypoxia and cancer. J Mol Med 2007; 85:1301-1307
2. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62.
3. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2:38-47. (Pubitemid 37328806)
4. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996; 56:941-943
5. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38:285-289 (Pubitemid 27318643)
6. Höckel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56:4509-4515 (Pubitemid 26330463)
7. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379:88-91. (Pubitemid 26008141)
8. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3:177-185 (Pubitemid 43316523)
9. Bindra RS, Schaffer PJ, Meng A, Woo J, Måseide K, Roth ME, et al. Alterations in DNA repair gene expression under hypoxia: elucidating the mechanisms of hypoxia-induced genetic instability. Ann NY Acad Sci 2005; 1059:184-195 (Pubitemid 43211621)
10. Tang N, Wang L, Esko J, Giordano FJ, Huang Y, Gerber HP, et al. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004; 6:485-495 (Pubitemid 39469984)
11. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003; 3:347-361 (Pubitemid 38340304)
12. Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J, et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 2005; 9:617-628 (Pubitemid 41555144)
13. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004; 14:198-206. (Pubitemid 38903223)
14. Trédan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99:1441-1454
15. Daruwalla J, Christophi C. Hyperbaric oxygen therapy for malignancy: a review. World J Surg 2006; 30:2112-2131 (Pubitemid 44885165)
16. Engert A. Recombinant human erythropoietin in oncology: current status and further developments. Ann Oncol 2005; 16:1584-1595 (Pubitemid 41510131)
17. Galluzzo M, Pennacchietti S, Rosano S, Comoglio PM, Michieli P. Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis. J Clin Invest 2009; 119:865-875
18. Wittenberg JB, Wittenberg BA. Myoglobin function reassessed. J Exp Biol 2003; 206:2011-2020
19. Ordway GA, Garry DJ. Myoglobin: an essential hemoprotein in striated muscle. J Exp Biol 2004; 207:3441-3446
20. Kooyman GL, Ponganis PJ. The physiological basis of diving to depth: birds and mammals. Annu Rev Physiol 1998; 60:19-32.
21. Hochachka PW. The metabolic implications of intracellular circulation. Proc Natl Acad Sci USA 1999; 96:12233-12239
22. Conley KE, Jones C. Myoglobin content and oxygen diffusion: model analysis of horse and steer muscle. Am J Physiol 1996; 271:2027-2036 (Pubitemid 126821266)
23. Merx MW, Flögel U, Stumpe T, Gödecke A, Decking UK, Schrader J. Myoglobin facilitates oxygen diffusion. FASEB J 2001; 15:1077-1079
24. Flögel U, Merx MW, Gödecke A, Decking UK, Schrader J. Myoglobin: A scavenger of bioactive NO. Proc Natl Acad Sci USA 2001; 98:735-740
25. Flögel U, Gödecke A, Klotz LO, Schrader J. Role of myoglobin in the antioxidant defense of the heart. FASEB J 2004; 18:1156-1158 (Pubitemid 39561555)
26. Percy MJ, McFerran NV, Lappin TR. Disorders of oxidised haemoglobin. Blood Rev 2005; 19:61-68
27. Gödecke A, Flögel U, Zanger K, Ding Z, Hirchenhain J, Decking UK, et al. Disruption of myoglobin in mice induces multiple compensatory mechanisms. Proc Natl Acad Sci USA 1999; 96:10495-10500 (Pubitemid 29422587)
28. Sidell BD, O'Brien KM. When bad things happen to good fish: the loss of hemoglobin and myoglobin expression in Antarctic icefishes. J Exp Biol 2006; 209:1791-1802
29. Axelson H, Fredlund E, Ovenberger M, Landberg G, Pahlman S. Hypoxia-induced dedifferentiation of tumor cells - a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol 2005; 16:554-563 (Pubitemid 41247879)
30. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008; 8:705-713
31. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186
32. Browder T, Folkman J, Hahnfeldt P, Heymach J, Hlatky L, Kieran M, et al. Antiangiogenic therapy and p53. Science 2002; 297:471.
33. Warburg O. On respiratory impairment in cancer cells. Science 1956; 124:269-270
34. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4:891-899
35. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-364 (Pubitemid 26272076)
36. Blagosklonny MV. How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy. Cancer Biol Ther 2005; 4:1307-1310
37. Kerbel RS. A cancer therapy resistant to resistance. Nature 1997; 390:335-336
38. Blagosklonny MV. Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy. Int J Oncol 2001; 19:257-262
39. Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell 2004; 5:13-17
40. Canning MT, Postovit LM, Clarke SH, Graham CH. Oxygen-mediated regulation of gelatinase and tissue inhibitor of metalloproteinases-1 expression by invasive cells. Exp Cell Res 2001; 267:88-94.
41. Maity A, Solomon D. Both increased stability and transcription contribute to the induction of the urokinase plasminogen activator receptor (uPAR) message by hypoxia. Exp Cell Res 2000; 255:250-257 (Pubitemid 30143858)
42. Graham CH, Fitzpatrick TE, McCrae KR. Hypoxia stimulates urokinase receptor expression through a heme protein-dependent pathway. Blood 1998; 91:3300-3307
43. Miyazaki Y, Hara A, Kato K, Oyama T, Yamada Y, Mori H, et al. The effect of hypoxic microenvironment on matrix metalloproteinase expression in xenografts of human oral squamous cell carcinoma. Int J Oncol 2008; 32:145-151 (Pubitemid 351176072)
44. Sprague LD, Tomaso H, Mengele K, Schilling D, Bayer C, Stadler P, et al. Effects of hypoxia and reoxygenation on the expression levels of the urokinasetype plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells. Oncol Rep 2007; 17:1259-1268
45. Muñoz-Nájar UM, Neurath KM, Vumbaca F, Claffey KP. Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Oncogene 2006; 25:2379-2392
46. Bottaro DP, Liotta LA. Cancer: Out of air is not out of action. Nature 2003; 423:593-595
47. Croager E. Low pressure warning. Nat Rev Cancer 2003; 3:398.
48. Wells WA. Metastasizing in search of oxygen. J Cell Biol 2003; 161:669.
49. Steeg PS. Angiogenesis inhibitors: motivators of metastasis? Nat Med 2003; 9:822-823
50. Kieran MW, Folkman J, Heymach J. Angiogenesis inhibitors and hypoxia. Nat Med 2003; 9:1104-1105
51. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8:299-309. (Pubitemid 41443415)
52. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-231
53. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15:232-239
54. Hayden EC. Cutting off cancer's supply lines. Nature 2009; 458:686-687
55. You WK, McDonald DM. The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep 2008; 41:833-839